MAP2K7 and melanoma: In BRAF-positive melanoma, Anti-PD-L1 atezolizumab in combination with the BRAF-MEK inhibitor vemurafenib + cobimetinib provided a survival advantage compared to placebo with the same combination of target therapy [12].